ArticleAntonie van Leeuwenhoek2025
Metabolite characterization of probiotic Enterococcus Faecium for targeting Salmonella Entrica gut bacteria causing gastroenteritis.
Article in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroenteritis is a prevalent digestive disorder that contributes to significant morbidity worldwide, often caused by pathogenic bacteria. Probiotics are increasingly recognized for their therapeutic potential in treating gastrointestinal diseases due to their beneficial effects on gut health. This study aimed to explore the antimicrobial, antioxidant, anti-diabetic, and anti-inflammatory properties of Enterococcus faecium metabolites, isolated from a milk sample, against Salmonella enterica. The bacterial strains were isolated using the streak plate method and molecularly characterized, with Enterococcus faecium showing 93.79% sequence similarity and Salmonella enterica showing 96.97% similarity in 16S rRNA sequencing. Metabolites of Enterococcus faecium were extracted using solvents such as ethanol, methanol, n-butanol, and ethyl acetate, resulting in 14 bioactive compounds, including lactic acid, acetic acid, and indole. Antimicrobial activity was evaluated via the disc diffusion method, revealing a dose-dependent increase in the zone of inhibition, reaching 20 mm at 100 µg/mL against Salmonella enterica. Antioxidant activity, assessed using the DPPH assay, exhibited a maximum scavenging rate of 99.8% at 550 µg/mL, while anti-diabetic activity showed 84.66% inhibition of alpha-amylase at 500 µg/mL. The anti-inflammatory activity demonstrated 99% inhibition of protein denaturation at the same concentration. No hemolytic activity was observed at lower concentrations, with the maximum hemolysis of 90% occurring at 250 µg/mL. In conclusion, Enterococcus faecium metabolites exhibited significant in vitro antimicrobial, antioxidant, anti-diabetic, and anti-inflammatory activities, indicating their promise as candidates for further investigation in the context of Salmonella enterica-induced gastroenteritis and related metabolic disorders. Future studies should focus on further clinical applications of these metabolites.
Indexed as
Identifiers
41128994What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.